March 24, 2025 10:57 AM EDT
News Briefing

Sur­rozen rais­es $175M, to fo­cus on oph­thal­mol­o­gy; CBC Group has a new $1B fund

ENDPOINTS

Plus, news about CG On­col­o­gy, Opus Ge­net­ics and Val­ne­va:

Sur­rozen’s piv­ot and cap­i­tal raise: The South San Fran­cis­co drug de­vel­op­er is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Lyn­dra Ther­a­peu­tics to wind down amid fund­ing hur­dles for long-act­ing drug tech­nol­o­gy

WuXi Bi­o­log­ics’ li­cens­ing deals help off­set Biose­cure threat in the US

Ei­sai cuts Leqem­bi 2027 sales fore­cast by half but ex­pects 'con­tin­ued growth'

Sen­ate com­mit­tee backs Dr. Oz's nom­i­na­tion to lead CMS

Mer­ck strikes deal for heart drug, worth up to $2B, with Chi­na’s Hen­grui

DOGE pulls three FDA lease clo­sures from 'Wall of Re­ceipts,' in­clud­ing St. Louis qual­i­ty lab

A service from the Financial Times